See more : Genus plc (GNS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Valeo Pharma Inc. (VPHIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valeo Pharma Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Northwest Biotherapeutics, Inc. (NWBO) Income Statement Analysis – Financial Results
- Belships ASA (NS6.F) Income Statement Analysis – Financial Results
- PT Guna Timur Raya Tbk (TRUK.JK) Income Statement Analysis – Financial Results
- The Toronto-Dominion Bank (TD.TO) Income Statement Analysis – Financial Results
- Saxlund Group AB (publ) (SAXG.ST) Income Statement Analysis – Financial Results
Valeo Pharma Inc. (VPHIF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.valeopharma.com
About Valeo Pharma Inc.
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 53.91M | 27.75M | 13.56M | 7.47M | 6.58M | 4.38M | 1.28M | 985.71K |
| Cost of Revenue | 40.83M | 21.46M | 9.60M | 6.09M | 5.18M | 3.55M | 747.09K | 2.35M |
| Gross Profit | 13.08M | 6.28M | 3.96M | 1.38M | 1.40M | 832.97K | 530.40K | -1.37M |
| Gross Profit Ratio | 24.26% | 22.64% | 29.17% | 18.49% | 21.30% | 19.01% | 41.52% | -138.68% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 126.26K | 0.00 |
| General & Administrative | 22.56M | 18.81M | 13.31M | 3.32M | 3.04M | 2.98M | 2.84M | 1.10M |
| Selling & Marketing | 6.59M | 6.09M | 2.89M | 2.12M | 2.01M | 236.53K | 133.75K | 72.75K |
| SG&A | 29.15M | 24.90M | 16.19M | 5.45M | 5.05M | 3.22M | 2.98M | 1.01M |
| Other Expenses | 1.15M | 0.00 | 123.00K | 198.00K | 253.00K | 147.04K | 50.77K | 0.00 |
| Operating Expenses | 30.31M | 25.39M | 16.65M | 5.68M | 5.14M | 3.26M | 3.14M | 1.01M |
| Cost & Expenses | 71.14M | 46.86M | 26.25M | 11.77M | 10.31M | 6.81M | 3.89M | 3.36M |
| Interest Income | 3.72M | 173.00K | 1.00K | 1.00K | 0.00 | 816.00 | 368.00 | 114.17K |
| Interest Expense | 13.79M | 6.46M | 1.36M | 598.00K | 110.00K | 173.85K | 102.42K | 0.00 |
| Depreciation & Amortization | 2.63M | 1.42M | 743.00K | 424.00K | 135.00K | 44.47K | 40.12K | 38.56K |
| EBITDA | -11.39M | -17.56M | -11.86M | -3.74M | -3.41M | -2.33M | -2.55M | -2.34M |
| EBITDA Ratio | -21.13% | -63.28% | -87.47% | -49.44% | -51.85% | -53.13% | -199.81% | -237.24% |
| Operating Income | -17.23M | -19.60M | -12.94M | -4.12M | -3.55M | -2.37M | -2.59M | -2.38M |
| Operating Income Ratio | -31.96% | -70.66% | -95.45% | -55.11% | -53.90% | -54.15% | -202.95% | -241.15% |
| Total Other Income/Expenses | -10.58M | -7.32M | -1.42M | -644.00K | 122.00K | 28.00K | -1.86M | 460.53K |
| Income Before Tax | -27.81M | -26.92M | -14.23M | -4.76M | -3.62M | -2.40M | -4.50M | -1.92M |
| Income Before Tax Ratio | -51.58% | -97.03% | -104.99% | -63.73% | -54.96% | -54.78% | -352.25% | -194.43% |
| Income Tax Expense | 0.00 | -1.17M | 1.48M | 796.00K | 326.00K | 36.72K | -881.21K | -640.00K |
| Net Income | -27.81M | -25.75M | -14.23M | -4.76M | -3.62M | -2.44M | -3.62M | -1.28M |
| Net Income Ratio | -51.58% | -92.80% | -104.99% | -63.73% | -54.96% | -55.62% | -283.27% | -129.50% |
| EPS | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | -0.05 | -0.07 | -0.03 |
| EPS Diluted | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | -0.05 | -0.07 | -0.03 |
| Weighted Avg Shares Out | 86.12M | 80.86M | 69.93M | 57.91M | 49.59M | 48.47M | 48.47M | 44.90M |
| Weighted Avg Shares Out (Dil) | 86.12M | 80.86M | 69.93M | 57.91M | 49.59M | 48.47M | 48.47M | 44.90M |
Valeo Pharma reports record revenue in 2Q, thanks to new product launches
Valeo Pharma closes bought-deal public offering for gross proceeds of $11.5M, including full exercise of over-allotment option
Valeo Pharma to Report Second Quarter 2021 Results and Hold Investors Conference Call / Webcast
Valeo Pharma poised for boost to financial performance as it commercially launches two asthma therapies
Valeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler®
Valeo Pharma gearing up for big growth with its strategy to bring prescription drugs to Canadian market
Valeo Pharma announces C$10M bought-deal public offering of its units
Valeo Pharma Announces $10.0 Million Bought-Deal Public Offering of Units
Valeo Pharma says private payer health plans covering 80% of Canadian market to reimburse for Enerzair Breezhaler and Atectura Breezhaler
Valeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler®
Source: https://incomestatements.info
Category: Stock Reports